Moderna FY2024 EPS Forecast Decreased by Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Investment analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for Moderna in a research note issued on Monday, January 13th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($9.61) per share for the year, down from their previous forecast of ($9.50). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna’s Q4 2024 earnings at ($3.28) EPS, Q1 2025 earnings at ($2.58) EPS, Q2 2025 earnings at ($2.56) EPS, Q3 2025 earnings at ($2.55) EPS, FY2025 earnings at ($10.28) EPS, FY2026 earnings at ($7.73) EPS and FY2027 earnings at ($4.13) EPS.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the previous year, the business earned ($1.39) earnings per share. Moderna’s revenue for the quarter was up 3.8% compared to the same quarter last year.

Several other research analysts have also recently issued reports on the company. Jefferies Financial Group dropped their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Friday, November 8th. JPMorgan Chase & Co. decreased their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research report on Tuesday, November 26th. Morgan Stanley dropped their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, Barclays reduced their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Four research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $76.68.

Moderna Stock Up 0.9 %

NASDAQ MRNA opened at $34.77 on Thursday. Moderna has a 12 month low of $31.94 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company’s 50 day simple moving average is $41.44 and its 200 day simple moving average is $67.56.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 2,664 shares of company stock valued at $115,210. 15.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently bought and sold shares of MRNA. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the 2nd quarter valued at about $26,000. Blue Trust Inc. boosted its position in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after purchasing an additional 574 shares during the period. Larson Financial Group LLC grew its holdings in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after purchasing an additional 778 shares during the period. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Moderna in the second quarter worth $75,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.